Drug Trial Radar · NCT06628362
A Study of Enicepatide (CT-388) in Participants Who Are Overweight or Obese With Type 2 Diabetes Mellitus
Last checked: Nov 19, 2026Latest source record: Oct 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
447
Actual
Start
Nov 21, 2024
Primary completion
May 29, 2026
Study completion Oct 2, 2026
Sponsor
- Lead sponsor
- Carmot Therapeutics, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Hoffmann-La Roche
- First posted
- Oct 8, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multi-center, randomized, double-blind, placebo-controlled, parallel group dose-finding study to evaluate the efficacy and safety of enicepatide at low, middle, and high doses in participants who are overweight or obese with Type 2 diabetes mellitus (T2DM).
Conditions
- Overweight or Obese
- Type 2 Diabetes Mellitus (T2DM)
Interventions
PlaceboDrug
Placebo will be volume-matched and administered subcutaneously (SC) once weekly.
EnicepatideDrug
Enicepatide will be administered subcutaneously (SC) once weekly at the randomized dosing regimen.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent Change in Body Weight from Baseline to Week 36Time frame: Baseline to Week 36
- Change in Glycated Hemoglobin (HbA1c) from Baseline to Week 36Time frame: Baseline to Week 36
Locations
70 sites in 6 countries. Site status is shown where the registry gives one.
Central Alabama Research
Birmingham, Alabama
University of Alabama at Birmingham (UAB)
Birmingham, Alabama
Lakeview Clinical Research, LLC
Guntersville, Alabama
Yuma Clinical Trials
Yuma, Arizona
AMCR Institute
Escondido, California
Ark Clinical-Fountain Valley
Fountain Valley, California
Orange Country Research Center
Lake Forest, California
Ark Clinical Research
Long Beach, California
Catalina Research Institute, LLC
Montclair, California
Asclepes Research Centers
Sherman Oaks, California
Encompass Clinical Research
Spring Valley, California
Flourish Research - Boca Raton
Boca Raton, Florida
Tampa Bay Medical Research
Clearwater, Florida
K2 Medical Research, LLC - Maitland
Maitland, Florida
K2 Medical Research, LLC - Orlando
Maitland, Florida
Flourish Research Acquisition, LLC
Miami, Florida
K2 Medical Research, LLC - South Orlando
Orlando, Florida
Aging Well Associates
St. Petersburg, Florida
K2 Medical Research Tampa
Tampa, Florida
K2 Summit Research
The Villages, Florida
Privia Medical Group Georgia, LLC
Fayetteville, Georgia
Privia Medical Group Georgia - Thomasville
Thomasville, Georgia
Rophe Adult and Pediatric Medicine/SKYCRNG
Union City, Georgia
Duly Health and Care
Lombard, Illinois
McFarland Clinic
Ames, Iowa
Cotton O'Neil Clinical Research Center
Topeka, Kansas
NOLA Cares, LLC
Metairie, Louisiana
Flourish Research Acquisition, LLC dba Flourish Bowie
Bowie, Maryland
Centennial Medical Group
Elkridge, Maryland
NECCR PrimaCare Research LLC
Fall River, Massachusetts
Olive Branch Family Medical Center; Family Medicine
Olive Branch, Mississippi
SKY Integrative Medical Center/SKYCRNG
Ridgeland, Mississippi
University of Nebraska Medical Center
Omaha, Nebraska
Ellipsis Research Group
Brooklyn, New York
Accellacare of Cary
Cary, North Carolina
Accellacare - Hickory
Hickory, North Carolina
Accellacare of Rocky Mount
Rocky Mount, North Carolina
Accellacare of Piedmont Healthcare
Statesville, North Carolina
Accellacare of Wilmington, LLC
Wilmington, North Carolina
Accellacare Research of Winston Salem
Winston-Salem, North Carolina
Showing 40 of 70 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.